COMPOUNDS CONTAINING AN ALICYCLIE STRUCTURE AND ANTI-TUMOR APPLICATION
申请人:Xu Lifeng
公开号:US20140045779A1
公开(公告)日:2014-02-13
This invention relates with anti-tumor activities of new compounds containing an adamantyl group or analogs thereof. The invention also relates with the medication applications of anti-tumor and other diseases by this kind of compounds with the combination of S, P, T structures containing adamantyl group and the formation of stereoisomer, tautomers, prodrug, pharmaceutically acceptable salts, complex salts or solvates to their anticancer application and anticancer agents, which have the following general formula:
An effective degradation reaction of CH2Cl2 by bispidine (3,7‐diazabicyclo[3.3.1]nonane, C7H12(NH)2, 1) is reported. The reaction starts as low as −20 °C and is quantitative with respect to 1. The overall reaction implies nucleophilic substitution of chloride, followed by a series of cascading acid–base reactions, ending with the formation of two easily separable products, one being soluble and the
Split-<i>Ugi</i>Reaction with Chiral Compounds: Synthesis of Piperazine- and Bispidine-Based Peptidomimetics
作者:Mattia Stucchi、Giordano Lesma
DOI:10.1002/hlca.201500505
日期:2016.4
stereoconservative synthesis of diamine‐based peptidomimetics is described, by split‐Ugi multicomponent reaction, involving chiral N‐protected amino acids and α‐substituted isocyanoacetate. In particular, piperazine and bispidine (3,7‐diazabicyclo[3.3.1]nonane) are exploited as diamine components, bispidine being the first example of a sterically demanding bicyclic system employed in a split‐Ugi reaction.